Equities research analysts at Rodman & Renshaw began coverage on shares of CytoDyn Inc. (OTCMKTS:CYDY) in a research report issued to clients and investors on Thursday. The brokerage set a “buy” rating and a $1.60 price target on the biotechnology company’s stock. Rodman & Renshaw’s price objective would suggest a potential upside of 125.35% from the company’s previous close.
CytoDyn (OTCMKTS:CYDY) opened at 0.71 on Thursday. The stock’s 50 day moving average is $0.87 and its 200 day moving average is $1.04. The company’s market cap is $88.42 million. CytoDyn has a 12-month low of $0.63 and a 12-month high of $1.57.
CytoDyn Company Profile
CytoDyn Inc is a biotechnology company focused on discovering and developing a class of therapeutic monoclonal antibodies to treats Human Immunodeficiency Virus (HIV) infection. Its lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors. These therapies potentially block HIV from entering into and infecting certain cells.
Receive News & Ratings for CytoDyn Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn Inc. and related companies with MarketBeat.com's FREE daily email newsletter.